nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.102	0.158	CbGbCtD
Atazanavir—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.102	0.158	CbGbCtD
Atazanavir—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.078	0.121	CbGbCtD
Atazanavir—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.077	0.12	CbGbCtD
Atazanavir—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0527	0.082	CbGbCtD
Atazanavir—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0503	0.0782	CbGbCtD
Atazanavir—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0448	0.0697	CbGbCtD
Atazanavir—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0439	0.0683	CbGbCtD
Atazanavir—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0414	0.0645	CbGbCtD
Atazanavir—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0263	0.0409	CbGbCtD
Atazanavir—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0248	0.0386	CbGbCtD
Atazanavir—Lopinavir—CYP1A2—chronic obstructive pulmonary disease	0.00257	0.453	CrCbGaD
Atazanavir—Ritonavir—CYP1A2—chronic obstructive pulmonary disease	0.00216	0.381	CrCbGaD
Atazanavir—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00177	0.062	CbGpPWpGaD
Atazanavir—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00157	0.0548	CbGpPWpGaD
Atazanavir—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00128	0.0448	CbGpPWpGaD
Atazanavir—SLCO1B3—Transport of organic anions—ALB—chronic obstructive pulmonary disease	0.00108	0.0378	CbGpPWpGaD
Atazanavir—Saquinavir—ALB—chronic obstructive pulmonary disease	0.000944	0.167	CrCbGaD
Atazanavir—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.000886	0.031	CbGpPWpGaD
Atazanavir—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.000823	0.0288	CbGpPWpGaD
Atazanavir—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.000807	0.0282	CbGpPWpGaD
Atazanavir—SLCO1B3—Recycling of bile acids and salts—ALB—chronic obstructive pulmonary disease	0.0008	0.028	CbGpPWpGaD
Atazanavir—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00065	0.0228	CbGpPWpGaD
Atazanavir—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000644	0.0225	CbGpPWpGaD
Atazanavir—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000586	0.0205	CbGpPWpGaD
Atazanavir—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000498	0.0174	CbGpPWpGaD
Atazanavir—ABCC1—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00046	0.0161	CbGpPWpGaD
Atazanavir—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000426	0.0149	CbGpPWpGaD
Atazanavir—SLCO1B3—Bile acid and bile salt metabolism—ALB—chronic obstructive pulmonary disease	0.000418	0.0146	CbGpPWpGaD
Atazanavir—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000417	0.00129	CcSEcCtD
Atazanavir—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000414	0.00128	CcSEcCtD
Atazanavir—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000414	0.00128	CcSEcCtD
Atazanavir—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000414	0.00128	CcSEcCtD
Atazanavir—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000413	0.00128	CcSEcCtD
Atazanavir—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000413	0.00128	CcSEcCtD
Atazanavir—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000412	0.00128	CcSEcCtD
Atazanavir—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000412	0.00127	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000411	0.00127	CcSEcCtD
Atazanavir—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00041	0.00127	CcSEcCtD
Atazanavir—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00041	0.0143	CbGpPWpGaD
Atazanavir—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000409	0.00126	CcSEcCtD
Atazanavir—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000409	0.00126	CcSEcCtD
Atazanavir—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000408	0.00126	CcSEcCtD
Atazanavir—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000405	0.00125	CcSEcCtD
Atazanavir—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000405	0.00125	CcSEcCtD
Atazanavir—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000404	0.00125	CcSEcCtD
Atazanavir—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.000404	0.00125	CcSEcCtD
Atazanavir—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000402	0.00124	CcSEcCtD
Atazanavir—Infection—Formoterol—chronic obstructive pulmonary disease	0.000402	0.00124	CcSEcCtD
Atazanavir—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—chronic obstructive pulmonary disease	0.000401	0.014	CbGpPWpGaD
Atazanavir—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00123	CcSEcCtD
Atazanavir—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00123	CcSEcCtD
Atazanavir—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.00123	CcSEcCtD
Atazanavir—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000398	0.00123	CcSEcCtD
Atazanavir—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000397	0.00123	CcSEcCtD
Atazanavir—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000397	0.00123	CcSEcCtD
Atazanavir—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000397	0.00123	CcSEcCtD
Atazanavir—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000396	0.00123	CcSEcCtD
Atazanavir—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000396	0.00123	CcSEcCtD
Atazanavir—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000394	0.00122	CcSEcCtD
Atazanavir—Infection—Montelukast—chronic obstructive pulmonary disease	0.000394	0.00122	CcSEcCtD
Atazanavir—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000393	0.00122	CcSEcCtD
Atazanavir—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00122	CcSEcCtD
Atazanavir—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00122	CcSEcCtD
Atazanavir—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000392	0.00121	CcSEcCtD
Atazanavir—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00039	0.00121	CcSEcCtD
Atazanavir—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000389	0.0012	CcSEcCtD
Atazanavir—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000389	0.0012	CcSEcCtD
Atazanavir—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000388	0.0012	CcSEcCtD
Atazanavir—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000387	0.0135	CbGpPWpGaD
Atazanavir—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00119	CcSEcCtD
Atazanavir—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000382	0.00118	CcSEcCtD
Atazanavir—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00038	0.00117	CcSEcCtD
Atazanavir—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000378	0.00117	CcSEcCtD
Atazanavir—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000376	0.00116	CcSEcCtD
Atazanavir—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.00116	CcSEcCtD
Atazanavir—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.00116	CcSEcCtD
Atazanavir—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000373	0.00115	CcSEcCtD
Atazanavir—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.00115	CcSEcCtD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000371	0.013	CbGpPWpGaD
Atazanavir—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00037	0.00114	CcSEcCtD
Atazanavir—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000369	0.00114	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000369	0.00114	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000369	0.00114	CcSEcCtD
Atazanavir—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000366	0.00113	CcSEcCtD
Atazanavir—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.00113	CcSEcCtD
Atazanavir—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00113	CcSEcCtD
Atazanavir—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000364	0.00113	CcSEcCtD
Atazanavir—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000362	0.00112	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000361	0.00112	CcSEcCtD
Atazanavir—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00112	CcSEcCtD
Atazanavir—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00112	CcSEcCtD
Atazanavir—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00036	0.00111	CcSEcCtD
Atazanavir—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00036	0.00111	CcSEcCtD
Atazanavir—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000359	0.00111	CcSEcCtD
Atazanavir—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.0011	CcSEcCtD
Atazanavir—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000356	0.0011	CcSEcCtD
Atazanavir—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000355	0.0011	CcSEcCtD
Atazanavir—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000352	0.00109	CcSEcCtD
Atazanavir—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000352	0.00109	CcSEcCtD
Atazanavir—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000351	0.00109	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00108	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00108	CcSEcCtD
Atazanavir—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000349	0.00108	CcSEcCtD
Atazanavir—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00108	CcSEcCtD
Atazanavir—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00108	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00108	CcSEcCtD
Atazanavir—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.00107	CcSEcCtD
Atazanavir—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000346	0.00107	CcSEcCtD
Atazanavir—Pain—Formoterol—chronic obstructive pulmonary disease	0.000346	0.00107	CcSEcCtD
Atazanavir—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.00107	CcSEcCtD
Atazanavir—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000346	0.00107	CcSEcCtD
Atazanavir—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000345	0.00107	CcSEcCtD
Atazanavir—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000345	0.00107	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000342	0.00106	CcSEcCtD
Atazanavir—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000342	0.00106	CcSEcCtD
Atazanavir—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00105	CcSEcCtD
Atazanavir—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00034	0.00105	CcSEcCtD
Atazanavir—ABCC1—S1P1 pathway—VEGFA—chronic obstructive pulmonary disease	0.00034	0.0119	CbGpPWpGaD
Atazanavir—Pain—Montelukast—chronic obstructive pulmonary disease	0.000339	0.00105	CcSEcCtD
Atazanavir—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000338	0.00105	CcSEcCtD
Atazanavir—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000337	0.00104	CcSEcCtD
Atazanavir—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00104	CcSEcCtD
Atazanavir—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00104	CcSEcCtD
Atazanavir—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000336	0.0117	CbGpPWpGaD
Atazanavir—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000335	0.00104	CcSEcCtD
Atazanavir—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000335	0.00104	CcSEcCtD
Atazanavir—ABCC1—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000334	0.0117	CbGpPWpGaD
Atazanavir—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000334	0.00103	CcSEcCtD
Atazanavir—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.00103	CcSEcCtD
Atazanavir—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000333	0.00103	CcSEcCtD
Atazanavir—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000332	0.00103	CcSEcCtD
Atazanavir—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000332	0.00103	CcSEcCtD
Atazanavir—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000331	0.00102	CcSEcCtD
Atazanavir—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000331	0.00102	CcSEcCtD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000331	0.0116	CbGpPWpGaD
Atazanavir—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00102	CcSEcCtD
Atazanavir—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00102	CcSEcCtD
Atazanavir—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000327	0.00101	CcSEcCtD
Atazanavir—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000327	0.00101	CcSEcCtD
Atazanavir—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000324	0.001	CcSEcCtD
Atazanavir—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000322	0.000995	CcSEcCtD
Atazanavir—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000322	0.000995	CcSEcCtD
Atazanavir—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00099	CcSEcCtD
Atazanavir—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00099	CcSEcCtD
Atazanavir—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00099	CcSEcCtD
Atazanavir—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00099	CcSEcCtD
Atazanavir—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000319	0.000987	CcSEcCtD
Atazanavir—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000319	0.000987	CcSEcCtD
Atazanavir—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000317	0.000979	CcSEcCtD
Atazanavir—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000316	0.000978	CcSEcCtD
Atazanavir—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000316	0.000978	CcSEcCtD
Atazanavir—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000316	0.000977	CcSEcCtD
Atazanavir—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000315	0.000974	CcSEcCtD
Atazanavir—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.000974	CcSEcCtD
Atazanavir—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000314	0.000972	CcSEcCtD
Atazanavir—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000313	0.00097	CcSEcCtD
Atazanavir—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000313	0.00097	CcSEcCtD
Atazanavir—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000313	0.000967	CcSEcCtD
Atazanavir—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000309	0.0108	CbGpPWpGaD
Atazanavir—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000954	CcSEcCtD
Atazanavir—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000307	0.00095	CcSEcCtD
Atazanavir—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000306	0.0107	CbGpPWpGaD
Atazanavir—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.000939	CcSEcCtD
Atazanavir—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.000935	CcSEcCtD
Atazanavir—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.000935	CcSEcCtD
Atazanavir—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000298	0.000923	CcSEcCtD
Atazanavir—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.000923	CcSEcCtD
Atazanavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000298	0.0104	CbGpPWpGaD
Atazanavir—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.000922	CcSEcCtD
Atazanavir—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000298	0.0104	CbGpPWpGaD
Atazanavir—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000297	0.000919	CcSEcCtD
Atazanavir—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000293	0.0102	CbGpPWpGaD
Atazanavir—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000292	0.000904	CcSEcCtD
Atazanavir—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.000899	CcSEcCtD
Atazanavir—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00029	0.000899	CcSEcCtD
Atazanavir—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000286	0.000886	CcSEcCtD
Atazanavir—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.000886	CcSEcCtD
Atazanavir—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000884	CcSEcCtD
Atazanavir—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000884	CcSEcCtD
Atazanavir—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000284	0.00088	CcSEcCtD
Atazanavir—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000282	0.000873	CcSEcCtD
Atazanavir—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.000871	CcSEcCtD
Atazanavir—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000281	0.00983	CbGpPWpGaD
Atazanavir—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00028	0.000868	CcSEcCtD
Atazanavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000279	0.00974	CbGpPWpGaD
Atazanavir—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000277	0.000857	CcSEcCtD
Atazanavir—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.000857	CcSEcCtD
Atazanavir—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000275	0.00085	CcSEcCtD
Atazanavir—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.000848	CcSEcCtD
Atazanavir—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000271	0.000839	CcSEcCtD
Atazanavir—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.000837	CcSEcCtD
Atazanavir—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00027	0.00945	CbGpPWpGaD
Atazanavir—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000268	0.000828	CcSEcCtD
Atazanavir—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000268	0.000828	CcSEcCtD
Atazanavir—ABCC1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000262	0.00918	CbGpPWpGaD
Atazanavir—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000262	0.000811	CcSEcCtD
Atazanavir—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00081	CcSEcCtD
Atazanavir—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.000809	CcSEcCtD
Atazanavir—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000258	0.000798	CcSEcCtD
Atazanavir—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.000796	CcSEcCtD
Atazanavir—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000257	0.000796	CcSEcCtD
Atazanavir—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.00079	CcSEcCtD
Atazanavir—Rash—Formoterol—chronic obstructive pulmonary disease	0.000255	0.00079	CcSEcCtD
Atazanavir—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000255	0.000789	CcSEcCtD
Atazanavir—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.000789	CcSEcCtD
Atazanavir—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000255	0.000789	CcSEcCtD
Atazanavir—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000254	0.000785	CcSEcCtD
Atazanavir—Headache—Formoterol—chronic obstructive pulmonary disease	0.000254	0.000785	CcSEcCtD
Atazanavir—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000784	CcSEcCtD
Atazanavir—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.000782	CcSEcCtD
Atazanavir—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000782	CcSEcCtD
Atazanavir—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000252	0.00078	CcSEcCtD
Atazanavir—Rash—Montelukast—chronic obstructive pulmonary disease	0.00025	0.000773	CcSEcCtD
Atazanavir—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00025	0.000773	CcSEcCtD
Atazanavir—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000249	0.000771	CcSEcCtD
Atazanavir—Depression—Prednisone—chronic obstructive pulmonary disease	0.000249	0.000771	CcSEcCtD
Atazanavir—Headache—Montelukast—chronic obstructive pulmonary disease	0.000248	0.000768	CcSEcCtD
Atazanavir—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.000759	CcSEcCtD
Atazanavir—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000757	CcSEcCtD
Atazanavir—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000244	0.00853	CbGpPWpGaD
Atazanavir—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.000752	CcSEcCtD
Atazanavir—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000242	0.000749	CcSEcCtD
Atazanavir—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.000746	CcSEcCtD
Atazanavir—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000241	0.000745	CcSEcCtD
Atazanavir—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.000745	CcSEcCtD
Atazanavir—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00024	0.000744	CcSEcCtD
Atazanavir—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.000744	CcSEcCtD
Atazanavir—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.000741	CcSEcCtD
Atazanavir—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.00073	CcSEcCtD
Atazanavir—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000235	0.000729	CcSEcCtD
Atazanavir—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000234	0.00819	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000234	0.00818	CbGpPWpGaD
Atazanavir—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000233	0.00072	CcSEcCtD
Atazanavir—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000232	0.000717	CcSEcCtD
Atazanavir—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.000702	CcSEcCtD
Atazanavir—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000226	0.000699	CcSEcCtD
Atazanavir—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000223	0.00069	CcSEcCtD
Atazanavir—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000222	0.00777	CbGpPWpGaD
Atazanavir—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00022	0.000682	CcSEcCtD
Atazanavir—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.000678	CcSEcCtD
Atazanavir—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.000667	CcSEcCtD
Atazanavir—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000212	0.000656	CcSEcCtD
Atazanavir—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000648	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000205	0.00717	CbGpPWpGaD
Atazanavir—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000205	0.00716	CbGpPWpGaD
Atazanavir—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.00714	CbGpPWpGaD
Atazanavir—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000629	CcSEcCtD
Atazanavir—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000627	CcSEcCtD
Atazanavir—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.000613	CcSEcCtD
Atazanavir—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000613	CcSEcCtD
Atazanavir—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000196	0.000608	CcSEcCtD
Atazanavir—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000196	0.00687	CbGpPWpGaD
Atazanavir—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000195	0.000604	CcSEcCtD
Atazanavir—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00058	CcSEcCtD
Atazanavir—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000186	0.00651	CbGpPWpGaD
Atazanavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000184	0.00643	CbGpPWpGaD
Atazanavir—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000181	0.00056	CcSEcCtD
Atazanavir—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000181	0.00633	CbGpPWpGaD
Atazanavir—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.000559	CcSEcCtD
Atazanavir—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000555	CcSEcCtD
Atazanavir—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000552	CcSEcCtD
Atazanavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000177	0.00619	CbGpPWpGaD
Atazanavir—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000176	0.000545	CcSEcCtD
Atazanavir—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000175	0.000542	CcSEcCtD
Atazanavir—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000174	0.0061	CbGpPWpGaD
Atazanavir—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.000539	CcSEcCtD
Atazanavir—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000531	CcSEcCtD
Atazanavir—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000171	0.00599	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.00017	0.00594	CbGpPWpGaD
Atazanavir—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000523	CcSEcCtD
Atazanavir—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000521	CcSEcCtD
Atazanavir—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000514	CcSEcCtD
Atazanavir—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000514	CcSEcCtD
Atazanavir—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000512	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000511	CcSEcCtD
Atazanavir—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000508	CcSEcCtD
Atazanavir—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.0005	CcSEcCtD
Atazanavir—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000159	0.000493	CcSEcCtD
Atazanavir—Infection—Prednisone—chronic obstructive pulmonary disease	0.000158	0.00049	CcSEcCtD
Atazanavir—Shock—Prednisone—chronic obstructive pulmonary disease	0.000157	0.000485	CcSEcCtD
Atazanavir—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000483	CcSEcCtD
Atazanavir—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000479	CcSEcCtD
Atazanavir—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000476	CcSEcCtD
Atazanavir—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00047	CcSEcCtD
Atazanavir—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000149	0.0052	CbGpPWpGaD
Atazanavir—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000449	CcSEcCtD
Atazanavir—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.000449	CcSEcCtD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000145	0.00507	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000144	0.00505	CbGpPWpGaD
Atazanavir—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000144	0.00505	CbGpPWpGaD
Atazanavir—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000144	0.000446	CcSEcCtD
Atazanavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00501	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—APIP—chronic obstructive pulmonary disease	0.000142	0.00496	CbGpPWpGaD
Atazanavir—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000434	CcSEcCtD
Atazanavir—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000138	0.000428	CcSEcCtD
Atazanavir—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000428	CcSEcCtD
Atazanavir—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000427	CcSEcCtD
Atazanavir—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000425	CcSEcCtD
Atazanavir—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000425	CcSEcCtD
Atazanavir—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000421	CcSEcCtD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000136	0.00476	CbGpPWpGaD
Atazanavir—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000406	CcSEcCtD
Atazanavir—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000403	CcSEcCtD
Atazanavir—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000403	CcSEcCtD
Atazanavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000128	0.00449	CbGpPWpGaD
Atazanavir—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.00444	CbGpPWpGaD
Atazanavir—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000392	CcSEcCtD
Atazanavir—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00039	CcSEcCtD
Atazanavir—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00039	CcSEcCtD
Atazanavir—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000125	0.00437	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000119	0.00417	CbGpPWpGaD
Atazanavir—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000363	CcSEcCtD
Atazanavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00408	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000116	0.00407	CbGpPWpGaD
Atazanavir—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000115	0.00403	CbGpPWpGaD
Atazanavir—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000354	CcSEcCtD
Atazanavir—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000349	CcSEcCtD
Atazanavir—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000111	0.00389	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000111	0.00387	CbGpPWpGaD
Atazanavir—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000337	CcSEcCtD
Atazanavir—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000326	CcSEcCtD
Atazanavir—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00367	CbGpPWpGaD
Atazanavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00364	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000103	0.00361	CbGpPWpGaD
Atazanavir—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000313	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	0.000101	0.00353	CbGpPWpGaD
Atazanavir—Rash—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000311	CcSEcCtD
Atazanavir—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.0001	0.00031	CcSEcCtD
Atazanavir—ABCC1—Metabolism—APIP—chronic obstructive pulmonary disease	0.0001	0.0035	CbGpPWpGaD
Atazanavir—Headache—Prednisone—chronic obstructive pulmonary disease	9.98e-05	0.000309	CcSEcCtD
Atazanavir—Nausea—Prednisone—chronic obstructive pulmonary disease	9.46e-05	0.000293	CcSEcCtD
Atazanavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	9.45e-05	0.00331	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.38e-05	0.00328	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	9.31e-05	0.00326	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	9.16e-05	0.00321	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GC—chronic obstructive pulmonary disease	9.13e-05	0.00319	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	9.06e-05	0.00317	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	8.68e-05	0.00304	CbGpPWpGaD
Atazanavir—SLCO1B3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	8.6e-05	0.00301	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.49e-05	0.00297	CbGpPWpGaD
Atazanavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.47e-05	0.00296	CbGpPWpGaD
Atazanavir—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.36e-05	0.00293	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	7.61e-05	0.00266	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	7.51e-05	0.00263	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	7.28e-05	0.00255	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	7.14e-05	0.0025	CbGpPWpGaD
Atazanavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.87e-05	0.0024	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	6.76e-05	0.00237	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.63e-05	0.00232	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	6.58e-05	0.0023	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GC—chronic obstructive pulmonary disease	6.45e-05	0.00226	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.44e-05	0.00225	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	6.36e-05	0.00223	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.35e-05	0.00222	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	6.26e-05	0.00219	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	6.11e-05	0.00214	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.04e-05	0.00211	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6e-05	0.0021	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.97e-05	0.00209	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	5.97e-05	0.00209	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.84e-05	0.00204	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.76e-05	0.00201	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.53e-05	0.00194	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.46e-05	0.00191	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	5.17e-05	0.00181	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.15e-05	0.0018	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.02e-05	0.00176	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.99e-05	0.00174	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.95e-05	0.00173	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GCLC—chronic obstructive pulmonary disease	4.93e-05	0.00172	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.78e-05	0.00167	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	4.76e-05	0.00167	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	4.74e-05	0.00166	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.6e-05	0.00161	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CTGF—chronic obstructive pulmonary disease	4.5e-05	0.00157	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	4.45e-05	0.00156	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	4.43e-05	0.00155	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.37e-05	0.00153	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.19e-05	0.00147	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.14e-05	0.00145	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.13e-05	0.00145	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.85e-05	0.00135	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.8e-05	0.00133	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.65e-05	0.00128	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.6e-05	0.00126	CbGpPWpGaD
Atazanavir—ABCC1—Disease—HDAC2—chronic obstructive pulmonary disease	3.54e-05	0.00124	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.53e-05	0.00123	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GCLC—chronic obstructive pulmonary disease	3.48e-05	0.00122	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.46e-05	0.00121	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.41e-05	0.00119	CbGpPWpGaD
Atazanavir—ABCC1—Disease—KL—chronic obstructive pulmonary disease	3.29e-05	0.00115	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.25e-05	0.00114	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CTGF—chronic obstructive pulmonary disease	3.18e-05	0.00111	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.18e-05	0.00111	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.17e-05	0.00111	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.16e-05	0.0011	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.09e-05	0.00108	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	3.07e-05	0.00107	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.01e-05	0.00105	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.95e-05	0.00103	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.94e-05	0.00103	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.93e-05	0.00103	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.92e-05	0.00102	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.87e-05	0.001	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.85e-05	0.000999	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.67e-05	0.000933	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.55e-05	0.000893	CbGpPWpGaD
Atazanavir—ABCC1—Disease—ERBB3—chronic obstructive pulmonary disease	2.47e-05	0.000863	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.45e-05	0.000856	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.44e-05	0.000855	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.41e-05	0.000843	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.34e-05	0.000819	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.3e-05	0.000803	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.25e-05	0.000786	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.19e-05	0.000765	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.13e-05	0.000745	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.12e-05	0.000743	CbGpPWpGaD
Atazanavir—ABCC1—Disease—NOS2—chronic obstructive pulmonary disease	2.06e-05	0.000719	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—ALB—chronic obstructive pulmonary disease	2.05e-05	0.000716	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—NOS3—chronic obstructive pulmonary disease	1.96e-05	0.000685	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.94e-05	0.00068	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.93e-05	0.000674	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.89e-05	0.000662	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.76e-05	0.000615	CbGpPWpGaD
Atazanavir—ABCC1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.73e-05	0.000606	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.68e-05	0.000587	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.66e-05	0.00058	CbGpPWpGaD
Atazanavir—ABCC1—Disease—NOS3—chronic obstructive pulmonary disease	1.65e-05	0.000578	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.57e-05	0.000548	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.55e-05	0.000542	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.51e-05	0.000529	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.47e-05	0.000514	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—ALB—chronic obstructive pulmonary disease	1.45e-05	0.000506	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.44e-05	0.000505	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000494	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.39e-05	0.000488	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.38e-05	0.000484	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.000456	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.16e-05	0.000407	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.15e-05	0.000401	CbGpPWpGaD
Atazanavir—ABCC1—Disease—TGFB1—chronic obstructive pulmonary disease	1.09e-05	0.000382	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.09e-05	0.00038	CbGpPWpGaD
Atazanavir—ABCC1—Disease—EGFR—chronic obstructive pulmonary disease	1.07e-05	0.000375	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000375	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.07e-05	0.000374	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.03e-05	0.000362	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.02e-05	0.000357	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.01e-05	0.000354	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.98e-06	0.000349	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.46e-06	0.000331	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	9.32e-06	0.000326	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.59e-06	0.0003	CbGpPWpGaD
Atazanavir—ABCC1—Disease—IL6—chronic obstructive pulmonary disease	8.24e-06	0.000288	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.16e-06	0.000251	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.06e-06	0.000247	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	6.88e-06	0.000241	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.59e-06	0.00023	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.58e-06	0.00023	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	6.43e-06	0.000225	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.24e-06	0.000218	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	6.15e-06	0.000215	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	4.24e-06	0.000148	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	4.06e-06	0.000142	CbGpPWpGaD
